5 results
Primary:• Compare progression-free survival (PFS) as assessed by the Independent Review Committee (IRC) per Response Evaluation Criteriain Solid Tumors (RECIST) Version (v) 1.1 in ociperlimab plus tislelizumab (Arm A) versus Durvalumab (Arm C) among…
Primary: To describe safety and tolerability during longer-term administration of AR101 and follow-up observation after the last dose of AR101.Secondary: - To assess the level of desensitization achievable through extended maintenance dosing of…
Primary Objective:To verify the accuracy and performance of the GlycostatTM System including its ability to secure good glycemic control by means of its algorithm. The accuracy of Glycostat, expressed by MARD (Mean Absolute Relative Difference), the…
Primary Objective:To determine if the time in the desired glycemic range is equivalent by following the insulin infusion rate advice from the Glycostat algorithm compared to historical data in the ICU. The historical data for glycemic control…
Primary:• To compare progression free survival (PFS) between Arm A (ociperlimab in combination with tislelizumab) and Arm B (pembrolizumab followed by placebo) in the Intent to Treat (ITT) Analysis Set as assessed by investigators according to…